4773288007_96679a394b_b

Fast-acting mealtime insulin approved for children with diabetes in Canada

pharmafile | March 10, 2020 | News story | Manufacturing and Production Type 1 diabetes, diabetes, insulin, insulin pump, type 2 diabetes 

Health Canada has approved Novo Nordik’s Fiasp, a faster acting mealtime insulin, for children aged 2 and above with type 1 or type 2 diabetes.

The regulatory body also approved Fiasp to include use in insulin infusion pumps for the improvement of glycemic control.

Dave Prowten, President and CEO of JDRF Canada, said on the approval: “We welcome the paediatric approval of Fiasp for younger Canadians, providing greater choice for effective disease management to support easier, healthier and safer lives for young people with type 1 diabetes.”

Health Canada’s approval is based on a review of the onset 7 clinical trial which confirmed the efficacy and safety of Fiasp in children. Fiasp vials may now be used for continuous subcutaneous insulin infusion in pump systems that are licensed in Canada for insulin infusion.

Vicky Chan, Vice President, Clinical Development, Medical and Regulatory Affairs, at Novo Nordisk Canada Inc, said: “We are pleased to offer Fiasp – a trusted and effective mealtime glucose control treatment – to the paediatric diabetes community in Canada allowing for choice and convenience in supporting diabetes management goals.” 

Fiasp was created with the goal to achieve a faster initial absorption rate, to improve glycaemic control after a meal, in people with diabetes.

Conor Kavanagh

 

Related Content

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Roche shares data on novel solution for continuous glucose monitoring

Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …

Latest content